TACSTD2 and primary biliary cholangitis: The Double Antibody Drug Conjugate (DAD) phase 1 trial (NCT04724018) combined sacituzumab govitecan (SG), which binds to Trop2 and is conjugated to the toxin SN-38, and EV in patients with aUC previously treated with PBC or immunotherapy [53].